TY - CHAP M1 - Book, Section TI - Assessing Drug Promotions A1 - Beckett, Robert D. A1 - Ness, Genevieve Lynn A2 - Malone, Patrick M. A2 - Malone, Meghan J. A2 - Park, Sharon K. PY - 2018 T2 - Drug Information: A Guide for Pharmacists, 6e AB - After completing this chapter, the reader will be able toDefine drug promotions.List recommendations by the World Health Organization (WHO) for appropriate drug promotions.Describe the role of the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP).Determine whether a piece of direct-to-consumer advertising (DTCA) has been cited in FDA warning letters to companies.Describe the allowed content for a specific type of DTCA.Evaluate a given piece of DTCA based on FDA and Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines.Report a drug promotion concern using the Bad Ad program.Evaluate the appropriateness of a piece of drug promotion designed for a health care professional.List systematic and individual strategies that may be used to combat proliferation of misinformation in drug promotions.Identify logical fallacies used in drug promotion, when given an interaction with a pharmaceutical industry representative.Describe the goals and design of academic detailing programs.Describe the clinical, economic, and humanistic effects of academic detailing. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1151746855 ER -